Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Combination therapy for type 2 diabetes: repaglinide plus rosiglitazone.

P Raskin1, J McGill, M F Saad

  • 1University of Texas, South western Medical Center, Dallas, TX, USA. philip.raskin@utsouth-western.edu

Diabetic Medicine : a Journal of the British Diabetic Association
|March 31, 2004
PubMed
Summary

Combination therapy with repaglinide and rosiglitazone significantly improved glycemic control in Type 2 diabetes patients who did not respond well to monotherapy. This repaglinide/rosiglitazone combination offers greater HbA1c reduction compared to monotherapy alone.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Dual-function natural biopolymers for aflatoxin M<sub>1</sub>: adsorption and diagnostic applications in milk.

The Journal of dairy research·2026
Same author

Decrease of AFM<sub>1</sub> concentration in cow milk by chitosan and bentonite clay application: impact on sensory and compositional attributes.

Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology]·2025
Same author

The first PET glimpse of a proton FLASH beam.

Physics in medicine and biology·2023
Same author

Assessment of safety and quality aspects of boiling treatment of quail eggs.

Letters in applied microbiology·2022
Same author

Prevalence of Bacillus cereus in dairy powders focusing on its toxigenic genes and antimicrobial resistance.

Archives of microbiology·2022
Same author

Both experimental hypo- and hyper-thyroidism exacerbate the adverse effects of chronic heat stress in broilers.

British poultry science·2019

Area of Science:

  • Endocrinology
  • Metabolic Diseases
  • Pharmacology

Background:

  • Type 2 diabetes management often requires combination therapy for patients with inadequate glycemic control on monotherapy.
  • Sulfonylurea and metformin are common first-line agents, but some patients exhibit unsatisfactory responses.

Purpose of the Study:

  • To compare the efficacy and safety of repaglinide monotherapy, rosiglitazone monotherapy, and a combination of repaglinide plus rosiglitazone.
  • To evaluate treatment outcomes in Type 2 diabetes patients with prior unsatisfactory response to oral monotherapy.

Main Methods:

  • A 24-week, randomized, multicenter, open-label, parallel-group clinical trial.
  • 252 adult patients with Type 2 diabetes and HbA1c > 7.0% after monotherapy were randomized to repaglinide, rosiglitazone, or combination therapy.

Related Experiment Videos

  • Efficacy was assessed by changes in HbA1c (primary) and fasting plasma glucose (secondary) after dose optimization and maintenance periods.

    • Main Results:

    • Combination therapy (repaglinide/rosiglitazone) achieved greater mean HbA1c reduction (-1.43%) compared to repaglinide (-0.17%) or rosiglitazone (-0.56%) monotherapy.
    • Fasting plasma glucose reductions were also significantly greater with combination therapy (-5.2 mmol/l) versus monotherapies.
    • Minor hypoglycemic events were observed in 9% of combination therapy patients, versus 6% for repaglinide and 2% for rosiglitazone.

    Conclusions:

    • Repaglinide/rosiglitazone combination therapy is well-tolerated and demonstrates superior glycemic reduction in Type 2 diabetes patients.
    • Combination therapy is an effective strategy for patients with insufficient response to oral antidiabetic monotherapy.